Literature DB >> 19330818

A comparison of echocardiographic findings in young adults with cardiomyopathy: with and without a history of methamphetamine abuse.

Hiroki Ito1, Khung-Keong Yeo, Mevan Wijetunga, Todd B Seto, Kevin Tay, Irwin J Schatz.   

Abstract

BACKGROUND: Methamphetamine is currently the most widespread illegal stimulant abused in the United States. No previous reports comparing echocardiographic findings of cardiomyopathy with and without a history of methamphetamine abuse are available.
METHODS: We performed a single institution retrospective review of medical records and analyses of echocardiographic findings in patients < or = 45 years of age hospitalized between 2001 and 2004 who were discharged with a diagnosis of cardiomyopathy or heart failure. After exclusion of patients with coronary artery disease or severe cardiac valvular disease, the remaining patients were divided into 2 groups based on their abuse or non abuse of methamphetamine, as determined by the documented history in the medical records or urine toxicology testing.
RESULTS: Among a total of 59 patients, 28 (47%) had a history of methamphetamine abuse or positive urine toxicology. Both methamphetamine abusers and non-abusers were predominately male (64.3% vs 64.5%, P = .99), and had a high prevalence of obesity (55.6% vs 73.3%, P = .16). Bivariate analysis revealed significant differences between the methamphetamine abusers and non-abusers in left atrium volume (119.7 +/- 55.4 ml vs 85.8 +/- 33.5 ml, P = .008), left ventricular end-diastolic volume (201.9 +/- 71.4 ml vs 156.6 +/- 63.1 ml, P = .01), left ventricular end-systolic volume (136.0 +/- 53.7 ml vs 92.3 +/- 55.8 ml, P = .004), right ventricular dimension (26.3 +/- 6.0 mm vs 21.3 +/- 6.0 mm, P = .007), and quantified left ventricular ejection fraction (32.9% +/- 11.3% vs 44.6% +/- 17.8%, P = .004).
CONCLUSIONS: We found a high prevalence of methamphetamine abuse in our study population. Methamphetamine abusers had echocardiographic findings of more severe dilated cardiomyopathy compared with non-abusers. 2009 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19330818      PMCID: PMC3787838          DOI: 10.1002/clc.20367

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  17 in total

1.  The association of methamphetamine use and cardiomyopathy in young patients.

Authors:  Khung-Keong Yeo; Mevan Wijetunga; Hiroki Ito; Jimmy T Efird; Kevin Tay; Todd B Seto; Kavitha Alimineti; Chieko Kimata; Irwin J Schatz
Journal:  Am J Med       Date:  2007-02       Impact factor: 4.965

2.  Cocaine activates calcium/calmodulin kinase II and causes cardiomyocyte hypertrophy.

Authors:  Robert J Henning; Javier Cuevas
Journal:  J Cardiovasc Pharmacol       Date:  2006-07       Impact factor: 3.105

3.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

Authors:  R B Devereux; D R Alonso; E M Lutas; G J Gottlieb; E Campo; I Sachs; N Reichek
Journal:  Am J Cardiol       Date:  1986-02-15       Impact factor: 2.778

4.  Reversible dilated cardiomyopathy induced by methamphetamine.

Authors:  L J Jacobs
Journal:  Clin Cardiol       Date:  1989-12       Impact factor: 2.882

5.  Prognostic value of left atrial enlargement in patients with idiopathic dilated cardiomyopathy and ischemic cardiomyopathy.

Authors:  Frank Lloyd Dini; Lauro Cortigiani; Umberto Baldini; Andrea Boni; Rossella Nuti; Luca Barsotti; Giovanni Micheli
Journal:  Am J Cardiol       Date:  2002-03-01       Impact factor: 2.778

6.  Cardiac lesions and their reversibility after long term administration of methamphetamine.

Authors:  M N Islam; H Kuroki; B Hongcheng; Y Ogura; N Kawaguchi; S Onishi; C Wakasugi
Journal:  Forensic Sci Int       Date:  1995-08-28       Impact factor: 2.395

Review 7.  Smokable methamphetamine ('ice'): an old drug in a different form.

Authors:  D K Beebe; E Walley
Journal:  Am Fam Physician       Date:  1995-02-01       Impact factor: 3.292

8.  Crystal methamphetamine-associated cardiomyopathy: tip of the iceberg?

Authors:  Mevan Wijetunga; Todd Seto; Joseph Lindsay; Irwin Schatz
Journal:  J Toxicol Clin Toxicol       Date:  2003

9.  Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy.

Authors:  Andrea Rossi; Mariantonietta Cicoira; Luisa Zanolla; Rita Sandrini; Giorgio Golia; Piero Zardini; Maurice Enriquez-Sarano
Journal:  J Am Coll Cardiol       Date:  2002-10-16       Impact factor: 24.094

10.  Cardiomyopathy associated with the smoking of crystal methamphetamine.

Authors:  R Hong; E Matsuyama; K Nur
Journal:  JAMA       Date:  1991-03-06       Impact factor: 56.272

View more
  21 in total

1.  Effect of methamphetamine dependence on heart rate variability.

Authors:  Brook L Henry; Arpi Minassian; William Perry
Journal:  Addict Biol       Date:  2010-12-23       Impact factor: 4.280

2.  Pattern of Methamphetamine Use and the Time Lag to Methamphetamine Dependence.

Authors:  Pongkwan Yimsaard; Michael M Maes; Viroj Verachai; Rasmon Kalayasiri
Journal:  J Addict Med       Date:  2018 Mar/Apr       Impact factor: 3.702

3.  Association of modifiable risk factors and left ventricular ejection fraction among hospitalized Native Hawaiians and Pacific Islanders with heart failure.

Authors:  Marjorie K L M Mau; Todd B Seto; Joseph K Kaholokula; Barbara Howard; Robert E Ratner
Journal:  Hawaii J Med Public Health       Date:  2014-12

Review 4.  Stimulant Drugs of Abuse and Cardiac Arrhythmias.

Authors:  Paari Dominic; Javaria Ahmad; Hajra Awwab; Md Shenuarin Bhuiyan; Christopher G Kevil; Nicholas E Goeders; Kevin S Murnane; James C Patterson; Kristin E Sandau; Rakesh Gopinathannair; Brian Olshansky
Journal:  Circ Arrhythm Electrophysiol       Date:  2021-12-28

5.  Methamphetamine and cardiac disease among people with HIV infection.

Authors:  Tcs Martin; S Gianella; D Franklin; P Hsue; D M Smith
Journal:  HIV Med       Date:  2020-08-01       Impact factor: 3.180

6.  The genetics of dilated cardiomyopathy: a prioritized candidate gene study of LMNA, TNNT2, TCAP, and PLN.

Authors:  Marika Hirtle-Lewis; Katia Desbiens; Isabelle Ruel; Nicholas Rudzicz; Jacques Genest; James C Engert; Nadia Giannetti
Journal:  Clin Cardiol       Date:  2013-08-27       Impact factor: 2.882

Review 7.  Methamphetamine-associated cardiomyopathy.

Authors:  Sekon Won; Robert A Hong; Ralph V Shohet; Todd B Seto; Nisha I Parikh
Journal:  Clin Cardiol       Date:  2013-08-27       Impact factor: 2.882

8.  The Combined Human Genotype of Truncating TTN and RBM20 Mutations Is Associated with Severe and Early Onset of Dilated Cardiomyopathy.

Authors:  Anna Gaertner; Julia Bloebaum; Andreas Brodehl; Baerbel Klauke; Katharina Sielemann; Astrid Kassner; Henrik Fox; Michiel Morshuis; Jens Tiesmeier; Uwe Schulz; Ralph Knoell; Jan Gummert; Hendrik Milting
Journal:  Genes (Basel)       Date:  2021-06-08       Impact factor: 4.096

9.  Report of methamphetamine use and cardiomyopathy in three patients.

Authors:  Roxana Sadeghi; Khosro Agin; Maryam Taherkhani; Leila Najm-Afshar; Lewis S Nelson; Mohammad Abdollahi; Shahin Shadnia
Journal:  Daru       Date:  2012-08-30       Impact factor: 3.117

10.  Clinical and echocardiographic outcomes in heart failure associated with methamphetamine use and cessation.

Authors:  Harpreet Singh Bhatia; Marin Nishimura; Stephen Dickson; Eric Adler; Barry Greenberg; Isac C Thomas
Journal:  Heart       Date:  2020-10-05       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.